These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 34564882

  • 41. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, Wai SH, Talaulikar D, Gasiorowski R, Cheah CY, Gregory GP, Dickinson M, Minson A, Coombes C, Ku M, Lam S, Hawkes EA.
    Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
    [Abstract] [Full Text] [Related]

  • 42. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
    Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M.
    Blood; 2019 Feb 28; 133(9):919-926. PubMed ID: 30617197
    [Abstract] [Full Text] [Related]

  • 43. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C.
    Ann Hematol; 2011 May 28; 90(5):539-46. PubMed ID: 20960190
    [Abstract] [Full Text] [Related]

  • 44. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
    Hu S, Song Y, Sun X, Su L, Zhang W, Jia J, Bai O, Yang S, Liang R, Li X, Zhang H, Gao Y, Zhang W, Xiao X, Bao H, Wang N, Ren H, Cen X, Yang S, Zhao Y, Wang Y, Wang Y, Liu A, Wang J, Shi Y, Yuan M, Li Y, He X.
    Cancer Sci; 2018 Dec 28; 109(12):3943-3952. PubMed ID: 30302857
    [Abstract] [Full Text] [Related]

  • 45. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA, Olszewski AJ.
    Curr Treat Options Oncol; 2018 Jun 21; 19(8):38. PubMed ID: 29931605
    [Abstract] [Full Text] [Related]

  • 46. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
    Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T.
    Clin Lymphoma Myeloma Leuk; 2015 Aug 21; 15(8):451-7. PubMed ID: 25816933
    [Abstract] [Full Text] [Related]

  • 47. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.
    Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, Lederlin P, Coiffier B.
    Ann Oncol; 2004 Jan 21; 15(1):129-33. PubMed ID: 14679132
    [Abstract] [Full Text] [Related]

  • 48. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
    Br J Haematol; 2015 Mar 21; 168(5):654-62. PubMed ID: 25312994
    [Abstract] [Full Text] [Related]

  • 49. Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study.
    Ma J, Li Q, Shao J, Ma Y, Lin Z, Kang H, Chen B.
    Cancer Manag Res; 2019 Mar 21; 11():10175-10185. PubMed ID: 31819650
    [Abstract] [Full Text] [Related]

  • 50. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
    Song J, Liu H, Shen HL, Yue LZ, Yang XJ, Song WJ, Sun CY, Yu SZ, Ding K, Wang YH, Li LJ, Yu H, Shao YY, Wang CM, Yue SY, Fu R.
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov 14; 42(11):917-922. PubMed ID: 35045653
    [Abstract] [Full Text] [Related]

  • 51. [Analysis of survival and treatment outcome of patients with primary diffuse large B cell lymphoma in reproductive system].
    Yang P, Zhen JF, Pang M, Hu K, Zhao W, Dong F, Tian L, Ke XY, Jing HM.
    Zhonghua Yi Xue Za Zhi; 2018 May 29; 98(20):1593-1596. PubMed ID: 29886651
    [Abstract] [Full Text] [Related]

  • 52. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N.
    Ann Oncol; 2007 Jan 29; 18(1):149-157. PubMed ID: 17018708
    [Abstract] [Full Text] [Related]

  • 53. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF.
    Br J Cancer; 2014 Sep 09; 111(6):1072-9. PubMed ID: 25072255
    [Abstract] [Full Text] [Related]

  • 54. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y.
    Cancer; 2012 Sep 01; 118(17):4166-72. PubMed ID: 22213346
    [Abstract] [Full Text] [Related]

  • 55. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N, Takasaki H, Ishiyama Y, Kishimoto K, Ishibashi D, Koyama S, Ishii Y, Takahashi H, Numata A, Watanabe R, Tachibana T, Ohshima R, Hagihara M, Hashimoto C, Takemura S, Taguchi J, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y.
    Leuk Lymphoma; 2015 Mar 01; 56(3):725-9. PubMed ID: 24913502
    [Abstract] [Full Text] [Related]

  • 56. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Uryu H, Mishima Y, Tsuyama N, Yokoyama M, Nishimura N, Fukuta T, Shirouchi Y, Okabe T, Inoue N, Takeuchi K, Terui Y.
    Leuk Lymphoma; 2021 Sep 01; 62(9):2141-2150. PubMed ID: 33749498
    [Abstract] [Full Text] [Related]

  • 57. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
    Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y.
    Leuk Lymphoma; 2020 Feb 01; 61(2):328-336. PubMed ID: 31533521
    [Abstract] [Full Text] [Related]

  • 58. Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.
    Yi JH, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ.
    Cytokine; 2020 May 01; 129():155048. PubMed ID: 32135464
    [Abstract] [Full Text] [Related]

  • 59. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R.
    Curr Treat Options Oncol; 2018 Sep 10; 19(11):52. PubMed ID: 30203318
    [Abstract] [Full Text] [Related]

  • 60. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
    Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.
    Ann Oncol; 2013 May 10; 24(5):1385-92. PubMed ID: 23247661
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.